Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mirza, W. U.
Right arrow Articles by Belendiuk, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mirza, W. U.
Right arrow Articles by Belendiuk, G. W.
NEUROLOGY 1998;51:1727-1729
© 1998 American Academy of Neurology

Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures

W. U. Mirza, MD, I. W. Rak, MD, V. M. Thadani, MD, J. J. Cereghino, MD, W. R. Garnett, PharmD, L. M. Brown, MD, Y. Zhang, PhD and G. W. Belendiuk, MD, PhD

From the Department of Neurology (Dr. Mirza), DePaul Hospital, Bridgeton, MO; Zeneca Pharmaceuticals (Dr. Rak), Wilmington, DE; Dartmouth-Hitchcock Medical Center (Dr. Thadani), Lebanon, NH; Epilepsy Center (Dr. Cereghino), Oregon Health Sciences University, Portland, OR; Department of Pharmacy and Pharmaceutics (Dr. Garnett), Medical College of Virginia, Virginia Commonwealth University, Richmond; and Shire Laboratories, Inc. (formerly Pharmavene Inc.) (Drs. Zhang and Belendiuk), Rockville, MD. Dr. Brown is in private practice in Portland, ME.

Address correspondence and reprint requests to Dr. Waqar Mirza, #845, 12255 DePaul Health Center, Department of Neurology, Bridgeton, MO 63044.

We evaluated the use of a new, controlled-release capsule form of carbamazepine, Carbatrol capsules, in an open-label, multicenter study of 124 patients with complex partial seizures. Ninety-one percent of the patients successfully completed the 6-month trial with good seizure control, with a significant improvement in quality of life. We conclude that switching patients with complex partial seizures from multiple daily-dose carbamazepine to twice-daily Carbatrol on a milligram-to-milligram basis is relatively safe.

Received February 11, 1998. Accepted in final form August 8, 1998.

{dagger}Deceased.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.